Clinical Trials Browser

Stomach Neoplasms

Fallopian Tube Neoplasms, Ovarian Neoplasms

Pancreatic Neoplasms

Prostatic Neoplasms

Nasopharyngeal Carcinoma

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

Breast Neoplasms

Bile Duct Neoplasms

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

Endometrial Carcinosarcoma

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Neoplasm Metastasis, Pancreatic Neoplasms, Endometrial Neoplasms

High Grade Serous Carcinoma

Carcinoma, Non-Small-Cell Lung

Uveal Melanoma

Carcinoma, Renal Cell, Kidney Neoplasms

Prostatic Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Solid Tumors

Prostatic Neoplasms

Breast Neoplasms

Glioblastoma

Ovarian Neoplasms

Triple Negative Breast Neoplasms

Osteosarcoma

Carcinosarcoma, Uterine Cervical Neoplasms, Endometrial Neoplasms, Carcinoma, Endometrioid

Fallopian Tube Neoplasms, Ovarian Neoplasms

Prostate Cancer, Hereditary, 7, Prostatic Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Ovarian Neoplasm Epithelial

Breast Neoplasms

Ovarian Neoplasms

Leiomyosarcoma

Breast Neoplasms

Prostatic Neoplasms

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

Prostatic Neoplasms

Breast Neoplasms

Fanconi Anemia, Complementation Group D1, Breast Neoplasms

Triple Negative Breast Neoplasms

Stomach Neoplasms

Non-small-cell Lung Cancer Patients

Liposarcoma, Neoplasms, Sarcoma

Breast Neoplasms, Neoplasm Metastasis

Squamous Cell Carcinoma of Head and Neck

Castration-Resistant Prostate Carcinoma

Breast Neoplasms, Triple Negative Breast Neoplasms

Pancreatic Neoplasms

Clinical Trials

Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers

An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib

Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.

Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects

POINT

TAPUR

A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer

Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations

Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis

I-SPY

A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

CAPRI

PIPSeN

Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma

ORCHID

Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)

RADIOLA

DAPA-ARMOR

Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)

Pembrolizumab, Olaparib, and Temozolomide for People With Glioma

Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer

Surgical Pembro +/- Olaparib w TMZ for rGBM

DOVACC

AMTEC IIT: Phase 2 Multiarm Study in TNBC

Olaparib With Ceralasertib in Recurrent Osteosarcoma

ATARI

Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC

A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer

FAB

PETREMAC

Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Chemotherapy and Olaparib as Neoadjuvant Therapy for Advanced Ovarian Cancer

DAPPER

Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer

Pembro With Radiation With or Without Olaparib

Pembrolizumab Plus Olaparib in LA-HNSCC

NePtune

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Olaparib In Metastatic Breast Cancer

Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC)

Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer

Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma

Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab

NeoSarc

ELEMENT

Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma

Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer

NeoADAPT

Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer